COMPASS Psilocybin Depression Data Excite Despite Safety Issues
The speed and efficacy of psilocybin candidate COMP360 in treatment-resistant depression in a Phase II study could outweigh the major safety events also seen.
You may also be interested in...
One of the best-attended sessions at the BIO meeting in San Diego saw psychedelics specialists weighing up the sector's chances of breaking taboos and getting to market.
PODCAST: Datamonitor Healthcare analysts explore the three key psychiatric disorder markets from current market leaders to promising pipeline candidates and novel mechanisms.
Podcast: Doug Drysdale, CEO of Cybin, tells Scrip about the controversial history of psychedelics and their potential role in addressing mental health disorders. The CEO also weighs in on consolidation in the psychedelic sector, which is currently dominated by biotech, and claims big pharma can no longer sit on the sidelines.